Quality-of-Life, Patient Preference, Tolerability,
and Safety Dimensions of

Desiccated Thyroid Extract (DTE)

Identifying Patients, Monitoring Approaches, and Optimizing
DTE-Based Treatment for Persons with Hypothyroidism

Thyroid Hormone Replacement

FEATURED AUTHORITIES ON HYPOTHYROIDISM
Click on Speaker to View Their iQ&A Sessions

Brittany Henderson, MD

Brittany Henderson, MD

Medical Director and Head Physician

Charleston Thyroid Center

Mount Pleasant, South Carolina

CAPT(ret) Thanh D. Hoang, DO, MACP, FACE

CAPT(ret) Thanh D. Hoang, DO, MACP, FACE

Professor of Medicine

Uniformed Services University of the Health Sciences

Director, Endocrinology Division

Uniformed Services University of the Health Sciences

Walter Reed National Military Medical Center

Endocrinology, Diabetes & Metabolism

Bethesda, MD

Francesco Saverio Celi, MD, MHSc

Francesco Saverio Celi, MD, MHSc

Professor of Medicine

Chair, Department of Medicine

James E. C. Walker Endowed Chair

University of Connecticut School of Medicine

Farmington, CT

Antonio C. Bianco, MD, PhD

Antonio C. Bianco, MD, PhD

Dean, John Sealy School of Medicine

Senior Vice President, Health Affairs

Chief Research Officer

Professor, Department of Internal Medicine – Endocrinology

The Robert A. Welch Distinguished University Chair in Chemistry

University of Texas Medical Branch

Galveston, TX


ACCESS RESOURCES IN THYROID HORMONE REPLACEMENT
ABOUT THIS PROGRAM AND FACULTY DISCLOSURES

    iQ&A interactive Medical Intelligence Zone welcomes your questions and your participation in the iQ&A community.

Latest Videos |view all videos

Showing 1 - 9 of 53 results

Previous| 1 | 2 | 3 | 4 | 5 ...6 |Next

Can you discuss initiating and sequencing thyroid hormone replacement—how you monitor patients, guideline-directed therapy, and the importance of metabolic and patient-centric factors in determining when DTE therapy should be considered? Video

Can you discuss initiating and sequencing thyroid hormone replacement—how you monitor patients, guideline-directed therapy, and the importance of metabolic and patient-centric factors in determining when DTE therapy should be considered?

Can you discuss initiating and sequencing thyroid hormone replacement—how you monitor patients, guideline-directed therapy, and the importance of metabolic and patient-centric factors in determining when DTE therapy should be considered?

Can you provide a perspective on what subset of patients treated with guideline-directed T4 monotherapy may continue to have persistent hypothyroid symptoms, how large this subpopulation is based on clinical studies, and how you rule out other causes of these symptoms? Video

Can you provide a perspective on what subset of patients treated with guideline-directed T4 monotherapy may continue to have persistent hypothyroid symptoms, how large this subpopulation is based on clinical studies, and how you rule out other causes of these symptoms?

Can you provide a perspective on what subset of patients treated with guideline-directed T4 monotherapy may continue to have persistent hypothyroid symptoms, how large this subpopulation is based on clinical studies, and how you rule out ...

Can you go into the specifics of the North Star trial, in terms of trial design, rationale, and what you were trying to assess as far as DTE-based treatment, including patients’ self-reported outcomes as well as FDA regulatory criteria for thyroid replacement in persons with hypothyroidism? Video

Can you go into the specifics of the North Star trial, in terms of trial design, rationale, and what you were trying to assess as far as DTE-based treatment, including patients’ self-reported outcomes as well as FDA regulatory criteria for thyroid replacement in persons with hypothyroidism?

Can you go into the specifics of the North Star trial, in terms of trial design, rationale, and what you were trying to assess as far as DTE-based treatment, including patients’ self-reported outcomes as well as FDA regulatory criteria ...

What is the alternative to using monotherapy with levothyroxine? And what role has desiccated thyroid extract (DTE) played historically in treating hypothyroidism, and what have we learned from this experience? Video

What is the alternative to using monotherapy with levothyroxine? And what role has desiccated thyroid extract (DTE) played historically in treating hypothyroidism, and what have we learned from this experience?

What is the alternative to using monotherapy with levothyroxine? And what role has desiccated thyroid extract (DTE) played historically in treating hypothyroidism, and what have we learned from this experience?

What are the trials, patient preference studies, and other evidence supporting your approach for deploying DTE in clinically appropriate populations, and in what percentage of patients with hypothyroidism does DTE become the treatment modality of choice? Video

What are the trials, patient preference studies, and other evidence supporting your approach for deploying DTE in clinically appropriate populations, and in what percentage of patients with hypothyroidism does DTE become the treatment modality of choice?

What are the trials, patient preference studies, and other evidence supporting your approach for deploying DTE in clinically appropriate populations, and in what percentage of patients with hypothyroidism does DTE become the treatment modality of choice?

Despite evidence-based guidelines for thyroid hormone replacement therapy, a significant percentage of patients fail to achieve acceptable/optimal symptom control with T4 monotherapy. What is the role for alternative combination approaches, such as DTE? Video

Despite evidence-based guidelines for thyroid hormone replacement therapy, a significant percentage of patients fail to achieve acceptable/optimal symptom control with T4 monotherapy. What is the role for alternative combination approaches, such as DTE?

Despite evidence-based guidelines for thyroid hormone replacement therapy, a significant percentage of patients fail to achieve acceptable/optimal symptom control with T4 monotherapy. What the role is for alternative combination approaches, such as DTE?

How do you decide in those patients in whom you believe combination T4/T3 therapy may be beneficial, whether you add T3 to T4 monotherapy or whether you commit you patients to DTE as the primary strategy for combination therapy? Video

How do you decide in those patients in whom you believe combination T4/T3 therapy may be beneficial, whether you add T3 to T4 monotherapy or whether you commit you patients to DTE as the primary strategy for combination therapy?

How do you decide in those patients in whom you believe combination T4/T3 therapy may be beneficial, whether you add T3 to T4 monotherapy or whether you commit you patients to DTE as the primary strategy for combination therapy?

What is causing the presence of 10-15% of patients with hypothyroidism who are dissatisfied with levothyroxine monotherapy? What is the role of T3 as a causative factor? And what are the implications for combination therapy and/or DTE? Video

What is causing the presence of 10-15% of patients with hypothyroidism who are dissatisfied with levothyroxine monotherapy? What is the role of T3 as a causative factor? And what are the implications for combination therapy and/or DTE?

What is causing the presence of 10-15% of patients with hypothyroidism who are dissatisfied with levothyroxine monotherapy? What is the role of T3 as a causative factor? And what are the implications for combination therapy and/or DTE?

What persistent hypothyroid-related symptoms do you look for to suggest T4 monotherapy may not be the optimal approach? Video

What persistent hypothyroid-related symptoms do you look for to suggest T4 monotherapy may not be the optimal approach?

What persistent hypothyroid-related symptoms do you look for to suggest T4 monotherapy may not be the optimal approach?

Showing 1 - 9 of 53 results

Previous| 1 | 2 | 3 | 4 | 5 ...6 |Next